Is Cingulate Inc. (CING) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 10.6% / 30% | 25.5% / 30% | 0.1% / 30% | N/A | ✓ HALAL |
| DJIM | 10.6% / 33% | 25.5% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| MSCI | 34.3% / 33% | 82.2% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| S&P | 10.6% / 33% | 25.5% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| FTSE | 34.3% / 33% | 82.2% / 33% | 0.2% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -450.6% | |
| Return on Assets (ROA) | -83.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$18M |
| Free Cash Flow | -$19M |
| Total Debt | $5M |
| Debt-to-Equity | 350.2 |
| Current Ratio | 1.2 |
| Total Assets | $15M |
Price & Trading
| Last Close | $6.28 |
| 50-Day MA | $6.68 |
| 200-Day MA | $4.78 |
| Avg Volume | 447K |
| Beta | -0.8 |
|
52-Week Range
$3.20
| |
About Cingulate Inc. (CING)
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Cingulate Inc. (CING) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Cingulate Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Cingulate Inc.'s debt ratio?
Cingulate Inc.'s debt ratio is 10.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 34.3%.
What are Cingulate Inc.'s key financial metrics?
Cingulate Inc. has a market capitalization of $74M. Return on equity stands at -450.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.